Russian Journal of Woman and Child Health
ISSN 2618-8430 (Print), 2686-7184 (Online)

Pre-pregnancy preparation in women with polycystic ovary syndrome and obesity: state-of-the-art

VAK

Scopus

E-libraryDOAJ

russian citation indexroad

ebscoULRICHS

cyberleninkagoogle-scholar

ВИНИТИРГБ

Open accessCrossrefAntiplagiat

RMJ.ru

License Creative Commons
All papers are licensed under a Creative Commons «Attribution» 4.0 License.


Impact factor - 1,090*

* Impact factor according to the SCIENCE INDEX 2022

DOI: 10.32364/2618-8430-2021-4-2-137-143

I.A. Lapina, T.G. Chirvon, Yu.E. Dobrokhotova, V.V. Taranov

Pirogov Russian National Research Medical University, Moscow, Russian Federation

In recent decades, extensive growth in the number of overweight or obese individuals is reported thus making this issue important for the medical community. According to some authors, 8% of overweight women and 18% of obese women have troubles with realizing reproductive function. Glucose and lipid metabolism disorders and hypertension that are common in women with polycystic ovary syndrome (PCOS) allow for referring this condition to metabolic diseases. Metabolic syndrome is an umbrella term for a set of metabolic abnormalities arising from insulin resistance and hyperinsulinemia. PCOS may also be considered as one of its manifestations being regarded as the most common cause of infertility in overweight and obese women. The treatment should be complex to recover reproductive function and to address metabolic disorders. Adherence to lifestyle changes, diet, and regular physical activity is still poor. Therefore, the use and assessment of the efficacy of pharmaceutical s for pre-pregnancy preparation to lose weight and to improve reproductive outcomes in PCOS.

Keywords: polycystic ovary syndrome, PCOS, obesity, metabolic syndrome, infertility, pre-pregnancy preparation, treatment, prevention, ovulation.

For citation: Lapina I.A., Chirvon T.G., Dobrokhotova Yu.E., Taranov V.V. Pre-pregnancy preparation in women with polycystic ovary syndrome and obesity: state-of-the-art. Russian Journal of Woman and Child Health. 2021;4(2):137–143. DOI: 10.32364/2618-8430-2021-4-2-137-143.



About the authors:

Irna A. Lapina — Cand. of Sci. (Med.), associate professor of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-2875-6307.

Tatyana G. Chirvon — postgraduate student of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-8302-7510.

Yuliya E. Dobrokhotova — Doct. of Sci. (Med.), Professor, Head of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-7830-2290.

Vladislav V. Taranov — postgraduate student of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0003-2338-2884.


Contact information: Irina A. Lapina, e-mail: doclapina@mail.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 06.03.2021, revised 21.03.2021, accepted 08.04.2021.



References
1. International evidence based guideline for the assessment and management of polycystic ovary syndrome. Copyright Monash University, Melbourne, Australia; 2018.
2. Domecq J.P., Prutsky G., Mullan R.J. et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4655–4663. DOI: 10.1210/jc.2013-2385.
3. Steinberg W.M., Rosenstock J., Wadden T.A. et al. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants with Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017;40(7):839–848. DOI: 10.2337/dc16-2684.
4. Le Roux C.W., Astrup A., Fujioka K. et al. SCALE Obesity Prediabetes NN8022–1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409. DOI: 10.1016/S0140-6736 (17) 30069-7.
5. Clark A., Ledger W., Galletly C. et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod. 1995;10(10):2705–2712. DOI: 10.1093/oxfordjournals.humrep.a135772.
6. Hutchison S., Stepto N.K., Harrisonet C.L. et al. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(1):E48–56. DOI: 10.1210/jc.2010-0828.
7. National Guideline Alliance, NICE Guideline. Eating Disorders: recognition and treatment. Methods, evidence and recommendations. National Institute for Health and Care Excellence: London; 2016.
8. Bazarganipour F., Taghavi S.A., Montazeri A. et al. The impact of polycystic ovary syndrome on the health-related quality of life: A systematic review and meta-analysis. Iran J Reprod Med. 2015;13(2):61–70. DOI: 10s-1030/-1571197.
9. Stepto N.K., Cassar S., Joham A. et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic hyper insulaemic clamp. Hum Reprod. 2013;28(3):777–784. DOI: 10.1093/humrep/des463.
10. Сапрыкина Л.В., Гульшин В.А. Возможности контроля овуляции у пациенток с синдромом поликистозных яичников на фоне терапии. РМЖ. 2018;5(I):29–32. [Saprykina L.V., Gulshin V.A. Possibilities of ovulation control in patients with polycystic ovary syndrome during therapy. RMJ. 2018;5(I):29–32 (in Russ.)].
11. Joham A., Palomba S., Hart R. Polycystic Ovary Syndrome, Obesity, and Pregnancy. Semin Reprod Med. 2016;34(02):93–101. DOI: 10.1055/s-0035-1571195.
12. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108(3):426–441. DOI: 10.1016/j.fertnstert.2017.06.026.
13. Hart R., Doherty D.A. The Potential Implications of a PCOS Diagnosis on a Woman’s Long-Term Health Using Data Linkage. J Clin Endocrinol Metab. 2015;100(3):911–919. DOI: 10.1210/jc.2014-3886.
14. Scheen A.J., Paquot N., Lefebvre P.J. United Kingdom Prospective Diabetes Study (UKPDS): 10 years later. Rev Med Liege. 2008;63(10):624–629.
15. Дедов И.И., Бутрова С.А. Синдром поликистозных яичников и метаболический синдром. Ожирение и метаболизм. 2006;1:30–40. [Dedov I.I., Butrova S.A. Polycystic ovary syndrome and metabolic syndrome. Ozhireniye i metabolizm. 2006;1:30–40 (in Russ.)].
16. Carvalho L., Ferreira C.N., de Oliveira D., Rodrigues K.D. Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome. J Assist Reprod Genet. 2017;34:1691–1698. DOI: 10.1007/s10815-017-1030-3.
17. Kebapcilar L., Taner C.E., Kebapcilar A.G., Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(2):187–193. DOI: 10.1007/s00404-008-0884-0.
18. Deligeoroglou E., Vrachnis N., Athanasopoulos N. et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol. 2012;28:974–978. DOI: 10.3109/09513590.2012.683082.
19. Moran L.J., Hutchison S.K., Meyer C., Zoungas S. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci. 2009;116:761–770. DOI: 10.4103/2231-0770.191445.
20. Ageno W., Di Minno M.N., Ay C. et al. Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysis. Arteriosclerosis, thrombosis, and vascular biology. 2014;34(11):2478–2485. DOI:10.1161/ATVBAHA.114.304085.
21. Moini A., Tadayon S., Tehranian A. et al. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Endocrinol. 2012;28(8):590–593. DOI: 10.3109/09513590.2011.650754.
22. Haynes M.C., Lu B.Y., Winkel A.F. Ovarian Vein Thrombophlebitis Related to Large Uterine Myoma. Obstet Gynecol. 2014;123(2 Pt 2 Suppl 2):450–453. DOI:10.1097/aog.00000000091.
23. Grandl G., Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018;40(2):215–224. DOI: 10.1007/s00281-017-0666-5.
24. Bañuls C., Rovira-Llopis S., Martinez de Marañon A. et al. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS. Metabolism. 2017;71:153–162. DOI: 10.1016/j.metabol.2017.02.012.
25. Лапина И.А., Озолиня Л.А., Доброхотова Ю.Э. и др. Комплексная оценка влияния гликозаминогликанов на систему гемостаза у пациенток с синдромом поликистозных яичников. Вопросы гинекологии, акушерства и перинатологии. 2019;5:35–41. [Lapina I.A., Ozolinya L.A., Dobrokhotova Yu.E. et al. Comprehensive assessment of the effect of glycosaminoglycans on the hemostatic system in patients with polycystic ovary syndrome. Voprosy ginekologii, akusherstva i perinatologii. 2019;5:35–41 (in Russ.)].
26. Jeanes Y.M., Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017;30(1):97–105. DOI: 10.1017/S0954422416000287.
27. Bailey A.P., Hawkins L.K., Missmer S.A. et al. Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. Am J Obstet Gynecol. 2014;211–213. DOI: 10.1016/j.ajog.2014.03.035.
28. He Y., Lu Y., Zhu Q. et al. Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women. Am J Obstet Gynecol. 2019;221(2):138.e1–138.e12. DOI: 10.1016/j.ajog.2019.03.011.
29. Anagnostis P., Tarlatzis B.C., Kauffman R.P. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33–43. DOI: 10.1016/j.metabol.2017.09.016.
30. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. DOI: 10.1093/humrep/deh098.
31. Rosenfield R.L., Ehrmann D.A. The pathogenesis of Polycystic Ovary Syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. DOI: 10.1210/er.2015-1104.
32. Moghetti P., Castello R., Negri C. et al. Metformin effectson clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovarysyndrome; a randomized, double-blind, placebo-controlled 6-month trial, followedby open, long-term clinical evaluation. J Clin Endocrinol Metabol. 2000;85:139–146. DOI: 10.1210/jcem.85.1.6293.
33. Foroozanfard F., Samimi M., Almadani K.H., Sehat M. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Physician. 2017;9(12):5969–5973. DOI: 10.19082/5969.
34. Nestler J.E., Powers L.P., Matt D.W. et al. A direct effectof hyperinsulinemia on serum sex hormone-binding globulinlevels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–89. DOI: 10.1210/jcem-72-1-83.
35. Pinola P. Hyperandrigenism, menstrual irregularities and polycystic ovary syndrome. Impact on female reproductive and metabolic health from early adultgood until menopause. University of Oulu, Juvenes Print. Tampere; 2016. DOI: 10.1093/humrep/deu200.
36. Morin-Papunen L.C., Vauhkonen I., Koivunen R.M. et al. Endocrine and metaboliceffects of metformin vs.ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metabol. 2000;85:316–318. DOI: 10.1016/j.metabol.2000.03.019.
37. O’Neil P.M., Birkenfeld A.L., McGowan B. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649. DOI: 10.1016/S0140-6736 (18) 31773-2.
38. Heimark D., McAllister J., Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111–117. DOI: 10.1507/endocrj.EJ13-0423.
39. Unfer V., Carlomagno G., Papaleo E. et al. Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci. 2014;21(7):854–858. DOI: 10.1177/1933719113518985.
40. Arya B.K., Haq A.U., Chaudhury K. Oocyte quality reflected by follicular fluid analysis in polycystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med Hypotheses. 2012;78(4):475–478. DOI: 10.1016/j.mehy.2012.01.009.
41. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;3095:2515–2516. DOI: 10.1016/j.fertnstert.2011.05.027.
42. Unfer V., Carlomagno G., Dante G. et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28:509–515. DOI: 10.3109/09513590.2011.650660.
43. Lagana A.S., Garzon S., Casarin J. et al. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol Metab. 2018;29(11):768–780. DOI: 10.1016/j.tem.2018.09.001.
44. Monastra G., Unfer V., Harrath A.H., Bizzarri M. Combining Treatment with Myo-Inositol and D-chiro-inositol (40:1). Is Effective in Restoring Ovary Function and Metabolic Balance in PCOS Patients. Gynecol Endocrinol. 2017;33(1):1–9. DOI: 10.1080/09513590.2016.1247797.
45. Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro- inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23 (12):5512–5521.
46. Facchinetti F., Appetecchia M., Aragona C. et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin Drug Metab Toxicol. 2020;16(3):255–274. DOI: 10.1080/17425255.2020.1737675.
47. Торшин И.Ю., Громова О.А., Калачева А.Г. и др. Мио-инозитол: микронутриент для «тонкой настройки» женской репродуктивной сферы. РМЖ. Мать и дитя. 2018;1(2):148–155. DOI: 10.32364/2618-8430-2018-1-2-148-155. [Torshin I.Yu., Gromova O.A., Kalacheva A.G. et al. Myo-inositol: micronutrient for “fine tuning” of the female reproductive sphere. Russian Journal of Woman and Child Health. 2018;1(2):148–155 (in Russ.)]. DOI: 10.32364/2618-8430-2018-1-2-148-155.
48. Венедиктова М.Г., Доброхотова Ю.Э. Онкогинекология в практике гинеколога. ГЭОТАР-МЕД; 2015. [Venediktova M.G., Dobrokhotova Yu.E. Oncogynecology in the practice of a gynecologist. GEOTAR-MED, 2015 (in Russ.)].



License Creative Commons
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous paper
Next paper

Register now and get access to useful services:
  • Загрузка полнотекстовых версий журналов (PDF)
  • Медицинские калькуляторы
  • Список избранных статей по Вашей специальности
  • Видеоконференции и многое другое

С нами уже 50 000 врачей из различных областей.
Присоединяйтесь!
[Error] 
Call to undefined function get_registration_form_description_popup() (0)
/home/c/cb72209/wchjournal/public_html/en/include/reg_form.php:89
#0: include
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/classes/general/main.php:1419
#1: CAllMain->IncludeFile(string)
	/home/c/cb72209/wchjournal/public_html/local/templates/.default/include/cl-footer.php:217
#2: include_once(string)
	/home/c/cb72209/wchjournal/public_html/local/templates/cl_inner_sidebar_en/footer.php:11
#3: include_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/include/epilog_before.php:93
#4: require(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/include/epilog.php:2
#5: require_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/footer.php:4
#6: require(string)
	/home/c/cb72209/wchjournal/public_html/en/articles/index.php:150
#7: include_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/include/urlrewrite.php:184
#8: include_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/urlrewrite.php:2
----------